New Launch11 Sept 2025, 05:31 am
Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
AI Summary
Biocon Limited, an innovation-led global biopharmaceutical company, has announced the inauguration of its first U.S. manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc. The facility, acquired from Eywa Pharma Inc. in 2023, has an annual production capacity of 2 billion tablets and has already commercialized a few products, with several more in the pipeline. This investment helps Biocon diversify its manufacturing base, strengthen its supply chain, and accelerate the expansion of its global footprint.
Key Highlights
- Biocon's first U.S. FDA approved formulations facility in New Jersey.
- Investment of over USD 30 million in a state-of-the-art plant.
- Annual production capacity of 2 billion tablets.
- Strategic advancement for Biocon’s U.S. operations.
- Enabling faster access to essential therapies and enhanced supply reliability in the U.S.